|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
|
DK2590676T3
(en)
|
2010-07-06 |
2016-10-24 |
Glaxosmithkline Biologicals Sa |
Virionlignende feed particles to self-replicating RNA molecules
|
|
RS54489B1
(sr)
|
2010-07-06 |
2016-06-30 |
Glaxosmithkline Biologicals Sa |
Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
|
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のｒｎａを用いた大型哺乳動物の免疫化
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
SMT202200311T1
(it)
|
2010-08-31 |
2022-09-14 |
Glaxosmithkline Biologicals Sa |
Liposomi pegilati per somministrare rna codificante un immunogene
|
|
HRP20221048T1
(hr)
*
|
2010-08-31 |
2022-11-11 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za isporuku rna koja kodira imunogen
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
EP3520813B1
(en)
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
EP3854413A1
(en)
*
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US20140141070A1
(en)
|
2011-07-06 |
2014-05-22 |
Andrew Geall |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
HK1206612A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
CN109045294A
(zh)
*
|
2013-01-10 |
2018-12-21 |
思齐乐 |
流感病毒免疫原性组合物及其应用
|
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US11155572B2
(en)
|
2013-03-15 |
2021-10-26 |
Glaxosmithkline Biologicals Sa |
RNA purification methods
|
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
KR102507624B1
(ko)
|
2013-11-22 |
2023-03-09 |
미나 테라퓨틱스 리미티드 |
Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
|
|
EP3798229A1
(en)
|
2014-03-25 |
2021-03-31 |
Yale University |
Uses of parasite macrophage migration inhibitory factors
|
|
RU2021109685A
(ru)
|
2014-04-23 |
2021-04-13 |
МОДЕРНАТиЭкс, ИНК. |
Вакцины на основе нуклеиновых кислот
|
|
EP2974739A1
(en)
|
2014-07-15 |
2016-01-20 |
Novartis AG |
RSVF trimerization domains
|
|
CN106456547B
(zh)
*
|
2014-07-02 |
2021-11-12 |
川斯勒佰尔公司 |
信使rna的包封
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
MA47016A
(fr)
|
2015-10-22 |
2018-08-29 |
Modernatx Inc |
Vaccins contre les virus respiratoires
|
|
BR112018008090A2
(pt)
*
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacina de vírus do herpes simplex.
|
|
JP6925688B2
(ja)
*
|
2015-10-22 |
2021-08-25 |
モデルナティーエックス， インコーポレイテッド |
水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
|
|
CA3003103A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
JP7687767B2
(ja)
*
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
CA3002819A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
|
LT3394093T
(lt)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
|
|
SG11201805217XA
(en)
|
2015-12-28 |
2018-07-30 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
EP3400023A1
(en)
|
2016-01-10 |
2018-11-14 |
ModernaTX, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018091540A1
(en)
|
2016-11-17 |
2018-05-24 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
ES2911186T3
(es)
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
|
KR102842382B1
(ko)
|
2017-03-24 |
2025-08-04 |
큐어백 에스이 |
Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
|
|
MX2019013259A
(es)
|
2017-05-08 |
2020-01-13 |
Gritstone Oncology Inc |
Vectores de neoantigeno de alfavirus.
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US11141377B2
(en)
*
|
2017-06-15 |
2021-10-12 |
Infectious Disease Research Institute |
Nanostructured lipid carriers and stable emulsions and uses thereof
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
EP4183882A1
(en)
|
2017-09-08 |
2023-05-24 |
MiNA Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
EP3681993A1
(en)
|
2017-09-13 |
2020-07-22 |
BioNTech RNA Pharmaceuticals GmbH |
Rna replicon for reprogramming somatic cells
|
|
AU2018333530B2
(en)
|
2017-09-13 |
2024-05-30 |
Biontech Cell & Gene Therapies Gmbh |
RNA replicon for expressing a T cell receptor or an artificial T cell receptor
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
US20220233568A1
(en)
|
2017-10-19 |
2022-07-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
EP4495597A3
(en)
|
2018-01-04 |
2025-04-30 |
Iconic Therapeutics LLC |
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
US12257266B2
(en)
|
2018-03-02 |
2025-03-25 |
The Regents Of The University Of California |
Stem cell-derived exosomes for the treatment of corneal scarring
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
CN113164584A
(zh)
|
2018-08-17 |
2021-07-23 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物及其用途
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
US12090235B2
(en)
*
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
WO2020146700A1
(en)
*
|
2019-01-10 |
2020-07-16 |
Massachusetts Institute Of Technology |
Lipid nanoparticles
|
|
WO2020144295A1
(en)
|
2019-01-10 |
2020-07-16 |
Biontech Rna Pharmaceuticals Gmbh |
Localized administration of rna molecules for therapy
|
|
KR20210134716A
(ko)
|
2019-03-01 |
2021-11-10 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드의 전달을 위한 조성물, 방법, 및 키트
|
|
MA55083A
(fr)
|
2019-03-01 |
2022-03-16 |
Flagship Pioneering Innovations Vi Llc |
Polyribonucléotides et leurs utilisations cosmétiques
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
JP7457733B2
(ja)
|
2019-05-30 |
2024-03-28 |
グリットストーン バイオ インコーポレイテッド |
改変アデノウイルス
|
|
AU2020318680B2
(en)
|
2019-07-21 |
2025-04-24 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
EP3819377A1
(en)
|
2019-11-08 |
2021-05-12 |
Justus-Liebig-Universität Gießen |
Circular rna and uses thereof for inhibiting rna-binding proteins
|
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
|
WO2021123920A1
(en)
|
2019-12-18 |
2021-06-24 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
JP2023517644A
(ja)
|
2020-03-09 |
2023-04-26 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
コロナウイルスワクチン組成物及び方法
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
EP4135761A1
(en)
|
2020-04-16 |
2023-02-22 |
GlaxoSmithKline Biologicals S.A. |
Sars cov-2 spike protein construct
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
EP4162034A1
(en)
|
2020-06-04 |
2023-04-12 |
BioNTech SE |
Rna replicon for versatile and efficient gene expression
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
WO2022002783A1
(en)
|
2020-06-29 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4189098A1
(en)
|
2020-07-27 |
2023-06-07 |
Anjarium Biosciences AG |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
EP4192496A4
(en)
|
2020-08-06 |
2025-01-01 |
Gritstone bio, Inc. |
MULTIEPITOP VACCINE CASSETTES
|
|
CN116171150A
(zh)
|
2020-08-14 |
2023-05-26 |
阿克丘勒斯治疗公司 |
冻干脂质纳米颗粒的方法
|
|
MX2023002439A
(es)
|
2020-09-03 |
2023-05-09 |
Flagship Pioneering Innovations Vi Llc |
Composiciones immunogénicas y usos de las mismas.
|
|
EP4008785A1
(en)
|
2020-12-03 |
2022-06-08 |
Justus-Liebig-Universität Gießen |
Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
EP4267593A2
(en)
|
2020-12-23 |
2023-11-01 |
GlaxoSmithKline Biologicals SA |
Self-amplifying messenger rna
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
JP2024511092A
(ja)
|
2021-03-26 |
2024-03-12 |
ミナ セラピューティクス リミテッド |
ＴＭＥＭ１７３ｓａＲＮＡ組成物及び使用方法
|
|
US20240181038A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
AU2022262422A1
(en)
*
|
2021-04-22 |
2023-11-02 |
The Board Of Regents Of The University Of Texas System |
All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
US20240285755A1
(en)
|
2021-05-24 |
2024-08-29 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
EP4352247A1
(en)
|
2021-06-09 |
2024-04-17 |
GlaxoSmithKline Biologicals s.a. |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
EP4359527A2
(en)
|
2021-06-23 |
2024-05-01 |
Novartis AG |
Compositions and methods for the treatment of hemoglobinopathies
|
|
WO2023021421A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
US20240350410A1
(en)
|
2021-08-16 |
2024-10-24 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
CN118043466A
(zh)
|
2021-09-03 |
2024-05-14 |
葛兰素史克生物有限公司 |
自扩增信使核糖核酸中核苷酸碱基的取代
|
|
JP2024539089A
(ja)
|
2021-10-18 |
2024-10-28 |
バイオエヌテック エスエー |
修飾複製可能ｒｎａの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用
|
|
CN118103516A
(zh)
|
2021-10-18 |
2024-05-28 |
生物技术欧洲股份公司 |
修饰的可复制rna和相关组合物及其用途
|
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
EP4482962A1
(en)
|
2022-02-24 |
2025-01-01 |
IO Biotech ApS |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
|
AU2023283348A1
(en)
|
2022-06-07 |
2025-01-09 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
JP2025532591A
(ja)
|
2022-09-15 |
2025-10-01 |
ビオンテック・ソシエタス・エウロパエア |
ｍｉＲＮＡを有するトランス増幅ＲＮＡベクターを含むシステムおよび組成物
|
|
JP2025532686A
(ja)
|
2022-09-26 |
2025-10-01 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス， インコーポレイテッド |
環状ｒｎａ組成物
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
CN120615013A
(zh)
|
2022-12-01 |
2025-09-09 |
世代生物公司 |
用于细胞靶向的隐形脂质纳米颗粒组合物
|
|
IL320873A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them
|
|
EP4626444A2
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
TW202440929A
(zh)
|
2022-12-14 |
2024-10-16 |
加拿大商普羅維登斯治療控股公司 |
用於感染性疾病的組合物和方法
|
|
CN120456919A
(zh)
|
2022-12-19 |
2025-08-08 |
葛兰素史克生物有限公司 |
乙型肝炎组合物
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
EP4701658A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
IL324411A
(en)
|
2023-05-05 |
2026-01-01 |
Sanofi Pasteur Inc |
Preparations for use in the treatment of acne
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
AU2024328030A1
(en)
|
2023-08-24 |
2026-03-12 |
BioNTech SE |
Systems and compositions comprising highly active trans-amplifying replicases
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025051381A1
(en)
|
2023-09-08 |
2025-03-13 |
BioNTech SE |
Methods and compositions for localized expression of administered rna
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106738A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
TW202539697A
(zh)
|
2023-11-15 |
2025-10-16 |
德商拜恩技術股份公司 |
冠狀病毒疫苗
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|